List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8469599/publications.pdf Version: 2024-02-01

		117625	123424
130	4,441	34	61
papers	citations	h-index	g-index
133	133	133	6494
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. Journal of Experimental Medicine, 2022, 219, .	8.5	37
2	MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma. Cell Death and Disease, 2022, 13, 63.	6.3	6
3	First Report of Testicular Replantation Following Wrong-Site Surgery. Urology, 2022, 164, 267-272.	1.0	4
4	Skeletal and Dental Outcomes after Facial Allotransplantation: The Cleveland Clinic Experience and Systematic Review of the Literature. Plastic and Reconstructive Surgery, 2022, 149, 945-962.	1.4	2
5	Pembrolizumab Compared with Standard-of-Care Observation in Treating Patients with Completely Resected Stage l–III Merkel Cell Cancer (STAMP). Annals of Surgical Oncology, 2022, 29, 3379-3380.	1.5	2
6	IL-17–induced HIF1α drives resistance to anti–PD-L1 via fibroblast-mediated immune exclusion. Journal of Experimental Medicine, 2022, 219, .	8.5	21
7	The Use and Technique of Sentinel Node Biopsy for Skin Cancer. Plastic and Reconstructive Surgery, 2022, 149, 995e-1008e.	1.4	0
8	Prophylactic lymphaticovenous bypass performed during complete lymphadenectomy is oncologically safe Journal of Clinical Oncology, 2022, 40, 9557-9557.	1.6	0
9	Germline predisposition in oncologic and dermatologic melanoma cohorts Journal of Clinical Oncology, 2022, 40, 10523-10523.	1.6	1
10	Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115 Journal of Clinical Oncology, 2022, 40, 9518-9518.	1.6	4
11	A phase 1b/2a study of safety and efficacy of NT-17 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naà ve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report Journal of Clinical Oncology, 2022, 40, 9561-9561.	1.6	4
12	Immunotherapy versus targeted therapy in the adjuvant setting for resected stage III melanoma: A single institution study Journal of Clinical Oncology, 2022, 40, e21578-e21578.	1.6	1
13	DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma Journal of Clinical Oncology, 2022, 40, TPS9594-TPS9594.	1.6	2
14	A retrospective cohort study of comprehensive peripheral and deep margin assessment in Merkel cell carcinoma: Standard margins may be unreliable. Journal of the American Academy of Dermatology, 2021, 84, 570-572.	1.2	5
15	Systemic blue hue after isosulfan use for lymphatic mapping in a case of metastatic melanoma excision. Microsurgery, 2021, 41, 100-101.	1.3	1
16	Disease Progression in Cutaneous Squamous Cell Carcinoma Patients With Satellitosis and In-transit Metastasis. Anticancer Research, 2021, 41, 289-295.	1.1	8
17	New Developments in the Management of Cutaneous Squamous Cell Carcinoma. Plastic and Reconstructive Surgery, 2021, 147, 492-504.	1.4	5
18	Successful Treatment of Life-Threatening COVID-19 Infection in a Face Transplant Recipient. Annals of Plastic Surgery, 2021, 87, 105-106.	0.9	3

BRIAN R GASTMAN

#	Article	IF	CITATIONS
19	Systemic Therapy for Head and Neck Skin Cancers. Face, 2021, 2, 121-130.	0.2	Ο
20	Indocyanine Green Fluorescence Imaging with Lymphoscintigraphy Improves the Accuracy of Sentinel Lymph Node Biopsy in Melanoma. Plastic and Reconstructive Surgery, 2021, 148, 83e-93e.	1.4	1
21	Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction. JCO Precision Oncology, 2021, 5, 1466-1479.	3.0	17
22	Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. , 2021, 9, e003272.		6
23	Non-Operative Options for Loco-regional Melanoma. Clinics in Plastic Surgery, 2021, 48, 631-642.	1.5	1
24	A Melanoma Update. Clinics in Plastic Surgery, 2021, 48, xiii-xiv.	1.5	1
25	Mixed Reality and 3D Printed Models for Planning and Execution of Face Transplantation. Annals of Surgery, 2021, 274, e1238-e1246.	4.2	20
26	NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 364-376.	4.9	167
27	The National Cancer Database: Survival Between Head and Neck Melanoma and Melanoma of Other Regions. Otolaryngology - Head and Neck Surgery, 2021, , 019459982110532.	1.9	1
28	Incidence and outcomes of cutaneous angiosarcoma: A SEER population-based study. Journal of the American Academy of Dermatology, 2020, 83, 809-816.	1.2	30
29	Lymphaticovenous Bypass for Immediate Lymphatic Reconstruction in Locoregional Advanced Melanoma Patients. Journal of Reconstructive Microsurgery, 2020, 36, 247-252.	1.8	24
30	Discussion: Guiding Strategies for the Future of Vascularized Composite Allotransplantation: A Systematic Review of Organ Donation Campaigns. Plastic and Reconstructive Surgery, 2020, 146, 935-936.	1.4	0
31	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
32	Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nature Cancer, 2020, 1, 1204-1217.	13.2	58
33	A Distinctive Lineage-Negative Cell Population Produces IL-17A in Cutaneous Squamous Cell Carcinoma. Journal of Interferon and Cytokine Research, 2020, 40, 418-424.	1.2	2
34	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). Melanoma Management, 2020, 7, MMT41.	0.5	3
35	Characterization of Face Transplant Candidates Evaluated at Cleveland Clinic and Algorithm to Maximize Efficacy of Screening Process. Annals of Plastic Surgery, 2020, 85, 561-567.	0.9	6
36	Tocilizumab therapy in 5 solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2. American Journal of Transplantation, 2020, 20, 3191-3197.	4.7	19

#	Article	IF	CITATIONS
37	Reply to Problematic methodology in a systematic review and meta-analysis of DecisionDx-Melanoma. Journal of the American Academy of Dermatology, 2020, 83, e359-e360.	1.2	1
38	Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database. Melanoma Research, 2020, 30, 376-385.	1.2	6
39	Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. Journal of the American Academy of Dermatology, 2020, 83, 745-753.	1.2	50
40	Targeted next generation sequencing (<scp>NGS</scp>) to classify melanocytic neoplasms. Journal of Cutaneous Pathology, 2020, 47, 691-704.	1.3	17
41	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 120-131.	4.9	11
42	Acute Superficial Vein Thrombosis of the Upper Extremity: A Case Report. Plastic and Reconstructive Surgery - Global Open, 2020, 8, e3322.	0.6	3
43	Neck Dissection and Parotidectomy for Melanoma. , 2020, , 689-704.		1
44	Indocyanine Green Fluorescence Imaging with Lymphoscintigraphy for Sentinel Node Biopsy in Melanoma: Increasing the Sentinel Lymph Node-Positive Rate. Annals of Surgical Oncology, 2019, 26, 3550-3560.	1.5	26
45	Sentinel lymph node biopsy in Merkel cell carcinoma: Predictors of sentinel lymph node positivity and association with overall survival. Journal of the American Academy of Dermatology, 2019, 81, 364-372.	1.2	33
46	Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases. Annals of Oncology, 2019, 30, 1399-1400.	1.2	12
47	Performance of a 31â€gene expression profile test in cutaneous melanomas of the head and neck. Head and Neck, 2019, 41, 871-879.	2.0	13
48	Response to: "Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients?― Journal of the American Academy of Dermatology, 2019, 80, e163-e164.	1.2	1
49	Histopathologic correlation of highâ€risk MelaFind TM lesions: a 3â€year experience from a highâ€risk pigmented lesion clinic. International Journal of Dermatology, 2019, 58, 569-576.	1.0	3
50	Experience with sternal plating and local flap reconstruction in patients with sternal dehisence. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2019, 72, 1436-1447.	1.0	0
51	Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer. Cancer Immunology Research, 2019, 7, 510-525.	3.4	47
52	Guidance of sentinel lymph node biopsy decisions in patients with T1–T2 melanoma using gene expression profiling. Future Oncology, 2019, 15, 1207-1217.	2.4	59
53	Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. JAMA Dermatology, 2019, 155, 442.	4.1	27
54	Face Transplantation for Granulomatosis With Polyangiitis (Wegener Granulomatosis). Annals of Plastic Surgery, 2019, 82, 320-329.	0.9	14

#	Article	IF	CITATIONS
55	Challenges in Microsurgical Reconstruction for Craniofacial Osteomyelitis With Resultant Osteonecrosis. Journal of Craniofacial Surgery, 2019, 30, 1960-1965.	0.7	2
56	Prognostic Significance of "Nonsolid―Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes. American Journal of Surgical Pathology, 2019, 43, 907-919.	3.7	2
57	The Timing of Alloplastic Cranioplasty in the Setting of Previous Osteomyelitis. Plastic and Reconstructive Surgery, 2019, 143, 853-861.	1.4	17
58	Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-l̂3. Cancer Immunology, Immunotherapy, 2019, 68, 395-405.	4.2	17
59	Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database. Journal of the American Academy of Dermatology, 2019, 80, 441-447.	1.2	37
60	IL-17R–EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells. Journal of Experimental Medicine, 2019, 216, 195-214.	8.5	82
61	Gene expression profiling in melanoma: past results and future potential. Future Oncology, 2019, 15, 791-800.	2.4	5
62	Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated Melanoma. American Journal of Dermatopathology, 2019, 41, 180-187.	0.6	1
63	Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. Oncolmmunology, 2019, 8, e1507669.	4.6	41
64	Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. Journal of the American Academy of Dermatology, 2019, 80, 149-157.e4.	1.2	72
65	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	4.9	326
66	Neck Dissection and Parotidectomy for Melanoma. , 2019, , 1-16.		0
67	Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma. Journal of the American Academy of Dermatology, 2018, 78, 942-948.	1.2	29
68	Determining the False-Negative Rate Using Fluorescence Image–Assisted Sentinel Lymph Node Biopsy in Cutaneous Melanoma. Annals of Plastic Surgery, 2018, 80, 54-58.	0.9	4
69	Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. Journal of the American Academy of Dermatology, 2018, 78, 40-46.e7.	1.2	95
70	Mixed Versus Pure Variants of Desmoplastic Melanoma. Annals of Plastic Surgery, 2018, 80, 277-281.	0.9	14
71	Singleâ€stage versus twoâ€stage arteriovenous loop microsurgical reconstruction: A metaâ€analysis of the literature. Microsurgery, 2018, 38, 706-717.	1.3	25
72	Suboptimal Outcomes in Cutaneous Squamous Cell Cancer of the Head and Neck with Nodal Metastases. Anticancer Research, 2018, 38, 5825-5830.	1.1	27

BRIAN R GASTMAN

#	Article	IF	CITATIONS
73	Long-term Outcomes of Cranioplasty. Annals of Plastic Surgery, 2018, 81, 416-422.	0.9	28
74	Indocyanine green fluorescence imaging with lymphoscintigraphy for sentinel node biopsy in head and neck melanoma. Journal of Surgical Research, 2018, 228, 77-83.	1.6	28
75	Malignant Melanoma: Diagnostic and Management Update. Plastic and Reconstructive Surgery, 2018, 142, 202e-216e.	1.4	45
76	Utilization of Indocyanine Green to Aid in Identifying Sentinel Lymph Nodes in Merkel Cell Cancer. Journal of Surgical Research, 2018, 232, 365-368.	1.6	5
77	Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. , 2018, 6, 36.		75
78	Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer, 2018, 18, 130.	2.6	117
79	Reply to: "Comment on 'Determination of the impact of melanoma surgical timing on survival using the National Cancer Database'― Journal of the American Academy of Dermatology, 2018, 79, e73-e74.	1.2	Ο
80	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 742-774.	4.9	202
81	A multiâ€institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer, 2017, 123, 2054-2060.	4.1	115
82	The Anterolateral Thigh Flap as the Flap of Choice for Scalp Reconstruction. Journal of Craniofacial Surgery, 2017, 28, 472-476.	0.7	28
83	Watershed Areas in Face Transplantation. Plastic and Reconstructive Surgery, 2017, 139, 711-721.	1.4	20
84	Identification of Risk Factors in Lymphatic Surgeries for Melanoma. Annals of Plastic Surgery, 2017, 79, 509-515.	0.9	10
85	Tumor-derived exosomes induce CD8+ T cell suppressors. , 2017, 5, 65.		133
86	Total Abdominal Wall Transplantation: An Anatomical Study and Classification System. Plastic and Reconstructive Surgery, 2017, 139, 1466-1473.	1.4	21
87	Mcl-1 regulates reactive oxygen species via NOX4 during chemotherapy-induced senescence. Oncotarget, 2017, 8, 28154-28168.	1.8	18
88	The Response of microRNAs to Solar UVR in Skin-Resident Melanocytes Differs between Melanoma Patients and Healthy Persons. PLoS ONE, 2016, 11, e0154915.	2.5	12
89	Malignant Pyoderma Associated with Granulomatosis with Polyangiitis (Wegener Granulomatosis) as a Unique Indication for Facial Vascularized Composite Allotransplantation: Part I. Plastic and Reconstructive Surgery, 2016, 137, 1007e-1015e.	1.4	11
90	NCCN Guidelines Insights: Melanoma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 945-958.	4.9	76

#	Article	IF	CITATIONS
91	Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient. Annals of Oncology, 2016, 27, 2304-2305.	1.2	19
92	Risk factors and outcomes of cutaneous melanoma in women less than 50Âyears of age. Journal of the American Academy of Dermatology, 2016, 74, 731-738.	1.2	34
93	Periocular Skin Cancer in Solid Organ Transplant Recipients. Ophthalmology, 2016, 123, 203-208.	5.2	10
94	Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients. Modern Pathology, 2016, 29, 122-130.	5.5	25
95	Management of Conjunctival Melanoma: Critical Assessment of Sentinel Lymph Node Biopsy. Ocular Oncology and Pathology, 2015, 1, 266-273.	1.0	18
96	Superior epigastric artery perforator (SEAP) flap: A novel approach to autologous breast reconstruction. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2015, 68, 519-524.	1.0	5
97	Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy. Journal of the American Academy of Dermatology, 2015, 73, 221-227.	1.2	64
98	Structure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain. Journal of Biological Chemistry, 2015, 290, 21962-21975.	3.4	15
99	A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4–ERK5 axis. Journal of Experimental Medicine, 2015, 212, 1571-1587.	8.5	170
100	Mcl-1 and tumor cell persistence. Oncotarget, 2015, 6, 5-6.	1.8	9
101	Complex Craniofacial Reconstruction Using Stereolithographic Modeling. Annals of Plastic Surgery, 2014, 72, 59-63.	0.9	5
102	A Modified Approach to Component Separation Using Biologic Graft as a Load-Sharing Onlay Reinforcement for the Repair of Complex Ventral Hernia. Surgical Innovation, 2014, 21, 137-146.	0.9	6
103	Sources of Federal Funding in Plastic and Reconstructive Surgery Research. Plastic and Reconstructive Surgery, 2014, 133, 1289-1294.	1.4	20
104	Advances in Diagnosis and Treatment of Nonmelanoma Skin Cancer. Annals of Plastic Surgery, 2014, 73, 615-619.	0.9	11
105	Indocyanine Green SPY Elite–Assisted Sentinel Lymph Node Biopsy in Cutaneous Melanoma. Plastic and Reconstructive Surgery, 2014, 133, 914-922.	1.4	61
106	Stereolithographic Modeling in Reconstructive Surgery of the Craniofacial Skeleton after Tumor Resection. Plastic and Reconstructive Surgery, 2012, 129, 743e-745e.	1.4	14
107	Extending the Cordeiro Maxillofacial Defect Classification System for Use in the Era of Vascularized Composite Transplantation. Plastic and Reconstructive Surgery, 2012, 130, 419-422.	1.4	9
108	Raiding the pharmacy: genomic screening identifies known chemotherapies as negative regulators of MCL1. Genome Medicine, 2012, 4, 53.	8.2	2

#	Article	IF	CITATIONS
109	Inhibition of Mcl-1 Promotes Senescence in Cancer Cells: Implications for Preventing Tumor Growth and Chemotherapy Resistance. Molecular and Cellular Biology, 2012, 32, 1879-1892.	2.3	46
110	Interleukin-7 Inhibits Tumor-Induced CD27â^'CD28â^' Suppressor T Cells: Implications for Cancer Immunotherapy. Clinical Cancer Research, 2011, 17, 4975-4986.	7.0	29
111	What Is the Best Surgical Margin for a Basal Cell Carcinoma: A Meta-Analysis of the Literature. Plastic and Reconstructive Surgery, 2010, 126, 1222-1231.	1.4	185
112	CD137 Promotes Proliferation and Survival of Human B Cells. Journal of Immunology, 2010, 184, 787-795.	0.8	60
113	Regulation of Mitochondrial Apoptotic Events by p53-mediated Disruption of Complexes between Antiapoptotic Bcl-2 Members and Bim. Journal of Biological Chemistry, 2010, 285, 22473-22483.	3.4	52
114	Isopentenyl Pyrophosphate–Activated CD56+ γδT Lymphocytes Display Potent Antitumor Activity toward Human Squamous Cell Carcinoma. Clinical Cancer Research, 2008, 14, 4232-4240.	7.0	143
115	Tumor-Induced Senescent T Cells with Suppressor Function: A Potential Form of Tumor Immune Evasion. Cancer Research, 2008, 68, 870-879.	0.9	93
116	Reconstruction of the marginal mandibulectomy defect: an update. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2007, 28, 363-366.	1.3	11
117	Conversion Furlow Palatoplasty. Annals of Plastic Surgery, 2006, 56, 505-510.	0.9	41
118	Reconstruction of the Lateral Mandibulectomy Defect: Management Based on Prognosis and Location and Volume of Soft Tissue Resection. Laryngoscope, 2006, 116, 2071-2080.	2.0	47
119	Interrelated Roles for Mcl-1 and BIM in Regulation of TRAIL-mediated Mitochondrial Apoptosis. Journal of Biological Chemistry, 2006, 281, 10153-10163.	3.4	161
120	Caspase Inhibition Enhances Ischemic Tolerance of Fasciocutaneous Flaps. Laryngoscope, 2005, 115, 1358-1361.	2.0	7
121	Disruption of Mcl-1·Bim Complex in Granzyme B-mediated Mitochondrial Apoptosis. Journal of Biological Chemistry, 2005, 280, 16383-16392.	3.4	60
122	Degradation of Mcl-1 by Granzyme B. Journal of Biological Chemistry, 2004, 279, 22020-22029.	3.4	90
123	A novel apoptotic pathway as defined by lectin cellular initiation. Biochemical and Biophysical Research Communications, 2004, 316, 263-271.	2.1	35
124	Apoptosis and Plastic Surgery. Plastic and Reconstructive Surgery, 2003, 111, 1481-1496.	1.4	7
125	Granzyme B-mediated degradation of T-cell receptor zeta chain. Cancer Research, 2002, 62, 4884-9.	0.9	39
126	Apoptosis-resistant Mitochondria in T Cells Selected for Resistance to Fas Signaling. Journal of Biological Chemistry, 2001, 276, 3610-3619.	3.4	29

#	Article	IF	CITATIONS
127	Resistance to Granzyme B-mediated Cytochrome c Release in Bak-deficient Cells. Journal of Experimental Medicine, 2001, 194, 1325-1338.	8.5	64
128	A Role for Mitochondrial Bak in Apoptotic Response to Anticancer Drugs. Journal of Biological Chemistry, 2001, 276, 34307-34317.	3.4	107
129	Tumor's other immune targets: dendritic cells. Journal of Leukocyte Biology, 1999, 66, 336-344.	3.3	92
130	Phase-Directed Therapy and Cardiac Xenograft Survival. Journal of Surgical Research, 1997, 72, 84-88.	1.6	5